Necrostatin-1 alleviates reperfusion injury following acute myocardial infarction in pigs

European Journal of Clinical Investigation

Volumn 45, Issue 2, 2015, Pages 150-159

  Koudstaal, Stefan ^a,b   Oerlemans, Martinus I F J ^a   Van der Spoel, Tycho I G ^a   Janssen, Aafke W F ^a   Hoefer, Imo E ^a   Doevendans, Pieter A ^a,b   Sluijter, Joost P G ^a,b   Chamuleau, Steven A J ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Cardioprotection; Myocardial infarction; Nec 1; Reperfusion injury

Indexed keywords

ENZYME INHIBITOR; NECROSTATIN 1; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; NECROSTATIN-1;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR MORTALITY; CELL DEATH; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; ECHOCARDIOGRAPHY; EXPERIMENTAL PIG; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; NECROPTOSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY; ANIMAL; CORONARY BLOOD VESSEL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HEART INFARCTION; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; LIGATION; MYOCARDIAL REPERFUSION INJURY; NEUTROPHIL; PATHOPHYSIOLOGY; PIG; RANDOMIZATION;

ANIMALS; CARDIOTONIC AGENTS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; FEMALE; HEMODYNAMICS; IMIDAZOLES; INDOLES; INFUSIONS, INTRAVENOUS; LIGATION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NEUTROPHILS; OXIDATIVE STRESS; RANDOM ALLOCATION; SUS SCROFA; SWINE;

EID: 84946160923     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12391     Document Type: Article

References (27)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129:e28-292.
2. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013;381:166-75.
3. Oerlemans MIFJ, Koudstaal S, Chamuleau SA, de Kleijn DP, Doevendans PA, Sluijter JPG. Targeting cell death in the reperfused heart: pharmacological approaches for cardioprotection. Int J Cardiol 2012;65:410-22.
4. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-35.
5. Hausenloy DJ, Ong S-B, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009;104:189-202.
6. Garcia-Dorado D, Ruiz-Meana M, Piper HM. Lethal reperfusion injury in acute myocardial infarction: facts and unresolved issues. Cardiovasc Res 2009;83:165-8.
7. Kung G, Konstantinidis K, Kitsis RN. Programmed necrosis, not apoptosis, in the heart. Circ Res 2011;108:1017-36.
8. Hausenloy DJ, Erik Bøtker H, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2013;98:7-27.
9. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005;1:112-9.
10. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014;370:455-65.
11. Smith CCT, Davidson SM, Lim SY, Simpkin JC, Hothersall JS, Yellon DM. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther 2007;21:227-33.
12. Kearney CJ, Cullen SP, Clancy D, Martin SJ. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis. FEBS J 2014;281:4921-34.
13. Tait SW, Oberst A, Quarato G, Milasta S, Haller M, Wang R et al. Widespread mitochondrial depletion via mitophagy does not compromise necroptosis. Cell Rep 2013;5:878-85.
14. Linkermann A, Brasen JH, Darding M, Jin MK, Sanz AB, Heller JO et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA 2013;110:12024-9.
15. Oerlemans MIFJ, Liu J, Arslan F, den Ouden K, van Middelaar BJ, Doevendans PA et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol 2012;107:270.
16. Luedde M, Lutz M, Carter N, Sosna J, Jacoby C, Vucur M et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res 2014;103:206-16.
17. Timmers L, Henriques JPS, de Kleijn DPV, Devries JH, Kemperman H, Steendijk P et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-10.
18. Arslan F, Houtgraaf JH, Keogh B, Kazemi K, de Jong R, McCormack WJ et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv 2012;5:279-87.
19. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiograph. J Am Soc Echocardiogr 2005;18:1440-63.
20. van der Spoel TIG, Vrijsen KR, Koudstaal S, Sluijter JPG, Nijsen JFW, de Jong HW et al. Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: a study on delivery efficiency. J Cell Mol Med 2012;16:2768-76.
21. Cleutjens JP, Blankesteijn WM, Daemen MJ, Smits JF. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 1999;44:232-41.
22. Lim SY, Davidson SM, Mocanu MM, Yellon DM, Smith CCT. The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore. Cardiovasc Drugs Ther 2007;21:467-9.
23. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010;87:406-23.
24. Hausenloy DJ, Baxter G, Bell R, Bøtker HE, Davidson SM, Downey J et al. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol 2010;105:677-86.
25. Davidovich P, Kearney CJ, Martin SJ. Inflammatory outcomes of apoptosis, necrosis and necroptosis. Biol Chem 2014;395:1163-71.
26. Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation 2011;124:1774-82.
27. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009;83:247-61.